Purple Biotech (PPBT) Total Current Liabilities (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Total Current Liabilities of $4.6 million for Q1 2026, up 66.53% year-over-year from $2.8 million in Q1 2025, and down 40.76% quarter-over-quarter from $7.8 million in Q4 2025.
Purple Biotech (PPBT) Total Current Liabilities (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Total Current Liabilities for 13 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 66.53% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (up 66.53% YoY), while the FY2025 annual figure was $7.8 million, up 94.46% from the prior year.
- Total Current Liabilities eased to $4.6 million in Q1 2026 per PPBT's latest filing, from $7.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $9.7 million in Q4 2023 and bottomed at $2.2 million in Q2 2025.
- Historically, Total Current Liabilities has averaged $5.9 million across 5 years, with a median of $5.9 million in 2022.
- On a YoY basis, Total Current Liabilities climbed as much as 94.46% in 2025 and fell as far as 67.59% in 2025.
- Purple Biotech's Total Current Liabilities stood at $7.1 million in 2022, then surged by 37.45% to $9.7 million in 2023, then plunged by 58.9% to $4.0 million in 2024, then surged by 94.46% to $7.8 million in 2025, then plunged by 40.76% to $4.6 million in 2026.
- Business Quant data shows PPBT's Total Current Liabilities at $4.6 million in Q1 2026, $7.8 million in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 1.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.59 Mn |
| Dec 31, 2025 | 7.75 Mn |
| Sep 30, 2025 | 6.06 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Mar 31, 2025 | 2.76 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 5.46 Mn |
| Jun 30, 2024 | 6.47 Mn |
| Mar 31, 2024 | 8.51 Mn |
| Dec 31, 2023 | 9.70 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Jun 30, 2023 | 4.88 Mn |
| Mar 31, 2023 | 5.62 Mn |
| Dec 31, 2022 | 7.06 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 5.39 Mn |
| Mar 31, 2022 | 7.19 Mn |
| Dec 31, 2021 | 4.25 Mn |
| Sep 30, 2021 | 3.43 Mn |
| Jun 30, 2021 | 3.50 Mn |